Immunogenomic Determinants of Response and Survival to PD-1 Blockade in Advanced Clear Cell RCC

May 29-31, 2020; Online at meetings.asco.org/am
PBRM1 mutations and del(9p21.3) associated with outcomes in advanced clear cell RCC treated with immune checkpoint inhibitors.
Format: Microsoft PowerPoint (.ppt)
File Size: 283 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Results from CheckMate 914 (Part A): adjuvant nivolumab plus ipilimumab vs placebo in resected stage II/III clear-cell RCC at high risk of recurrence, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings